BAGSVAERD, Denmark, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the 11 September 2014 Advisory Committee meeting to discuss the New Drug Application (NDA) for Saxenda®, the intended brand name forliraglutide 3 mg for the treatment of obesity.
Further information
Media: | ||
Mike Rulis | +45 3079 3573 | mike@novonordisk.com |
Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Jannick Lindegaard Denholt | +45 3079 8519 | jlis@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com |
Company announcement No 55 / 2014
Company announcement No 55 / 2014 http://hugin.info/2013/R/1854659/648657.pdf
HUG#1854659